Healthcare providers already seeing the benefits of AI

AI technologies are already having a direct, significant impact on patient care, according to a new report from MIT Technology Review and GE Healthcare.

More than 900 healthcare professionals from throughout the United States and U.K. were surveyed for the report in October 2019. While 17% of respondents were medical doctors and specialists, another 26% were in senior management positions and 16% were IT specialists.

Overall, 78% of medical employees who have already implemented AI said it has led to immediate workflow improvements. Seventy-five percent said AI has “enabled better predictions in the treatment of disease.” AI also appears to be encouraging collaboration among healthcare providers, with 68% of respondents saying they are working more regularly with colleagues from other clinical care areas.

“Of any industry, AI could have the most profound benefits on human lives if we can effectively harness it across the healthcare system,” Kieran Murphy, president and CEO of GE Healthcare, said in a prepared statement. “As this research shows, we are already beginning to see its progressive effect—with AI not only fueling efficiencies within health systems, but also truly evolving the healthcare experience for medical professionals and patients.”

More information on the report’s findings is available on the MIT Technology Review website.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.